急性白血病与免疫干细胞表型的疗效相关性及预后分析  

The curative effect of acute leukemia and immune cells phenotypic correlation and prognostic analysis

作　　者：郭天剑[1] 龚峻梅[1] 吴必嘉[1] 

机构地区：[1]解放军第421医院血液内科,广州510310

出　　处：《中国医学前沿杂志（电子版）》2014年第7期131-133,共3页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的研究不同免疫干细胞表型的急性白血病患者的治疗效果及预后情况。方法将本院2010年1月至2013年12月收治的78例急性白血病患者作为研究对象,检测其免疫干细胞表型,并记录治疗情况。结果急性白血病免疫干细胞表型CD34+的患者比例最高(71.39%),其次为CD33+、CD64+患者;免疫干细胞CD33、CD64、CD34、CD19呈阳性的患者治愈率均低于其表型呈阴性的患者,差异具有显著性(t=11.1682,9.5098,10.6997,7.2341;P=0.0008,0.0020,0.0011,0.0072);免疫干细胞表型CD34+CD19+患者的治愈率高于CD34+CD19-的患者;而CD34+CD64+患者的治愈率低于CD34+CD64-的患者,差异具有显著性(t=6.9115,6.3096;P=0.0086,0.0120)。结论不同免疫干细胞表型的急性白血病患者的治愈率不同,免疫干细胞表型与急性白血病患者的治疗效果、预后密切相关。Objective Patients with acute leukemia treatment effect and prognosis of different phenotypes of immune. Method 78 cases of acute leukemia patients in our hospital from January 2010 to December 2013 as the research object, its immune stemcell phenotype was detected, and record the treatment situation. Result Immune in patients with acute leukemia stem cell phenotype in patients with CD34^＋ the highest proportion（71.39%）, followed by CD33^＋, CD64^＋; CD33, CD64 in patients with immune cells, CD34, CD19 positive patients, the cure rate was lower than the phenotypic negative patients, the difference was significant（t = 11.1682, 9.5098, 10.6997, 7.2341; P = 0.0008, 0.0020, 0.0011, 0.0072）; cure the patients immune stem cellphenotype of CD34^＋CD19^＋ was higher than that of the CD34^＋CD19^-patients; and the healing rate of the patients with CD34^＋CD64^＋ than patients with CD34^＋CD64^-, and the difference was significant（t = 6.9115, 6.3096; P = 0.0086, 0.0120）. Conclusion The cure rate of patients with acute leukemia cell phenotype different immune stem of different immune in patients with acute leukemia, stem cell phenotype, the treatment effect is closely related to the prognosis.

关 键 词：急性白血病 免疫干细胞 表型 疗效 

分 类 号：R733.71[医药卫生—肿瘤]